Supernus Pharmaceuticals's market cap is currently ―. The company's EPS TTM is $-0.284; its P/E ratio is -93.42; Supernus Pharmaceuticals is scheduled to report earnings on August 6, 2024, and the estimated EPS forecast is $0.39. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 143.64M	$ 153.88M	$ 135.56M	$ 153.76M	$ 167.33M
Gross Profit	$ 127.33M	$ 134.28M	$ 114.47M	$ 130.30M	$ 144.37M
EBIT	$ 243.00K	$ 9.89M	$ -16.22M	$ 10.52M	$ 25.01M
EBITDA	$ 20.99M	$ 31.78M	$ 4.51M	$ 31.62M	$ 45.71M
Net Income Common Stockholders	$ 124.00K	$ -15.98M	$ -831.00K	$ 16.95M	$ 25.48M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 297.74M	$ 200.19M	$ 151.66M	$ 58.44M	$ 461.33M
Total Assets	$ 1.30B	$ 1.29B	$ 1.29B	$ 1.79B	$ 1.70B
Total Debt	$ 32.99M	$ 33.84M	$ 34.18M	$ 741.66M	$ 437.97M
Net Debt	$ -264.74M	$ -166.35M	$ -117.48M	$ 683.22M	$ -23.37M
Total Liabilities	$ 374.92M	$ 372.97M	$ 373.19M	$ 879.66M	$ 816.30M
Stockholders Equity	$ 929.17M	$ 912.19M	$ 919.91M	$ 912.15M	$ 886.20M
Cash Flow	-
Free Cash Flow	$ 38.15M	$ 35.73M	$ -19.82M	$ 50.46M	$ 27.56M
Operating Cash Flow	$ 38.40M	$ 35.88M	$ -19.66M	$ 50.74M	$ 27.56M
Investing Cash Flow	$ -51.62M	$ 34.63M	$ 61.09M	$ 238.13M	$ -48.77M
Financing Cash Flow	$ 1.57M	$ -230.00K	$ -478.92M	$ 80.17M	$ 2.83M

Currency in USD

Supernus Pharmaceuticals Earnings and Revenue History

Income Statement >

Supernus Pharmaceuticals Debt to Assets

Balance Sheet >

Supernus Pharmaceuticals Cash Flow

Cash Flow >

Supernus Pharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing